JP2014528714A5 - - Google Patents

Info

Publication number

JP2014528714A5

JP2014528714A5 JP2014530731A JP2014530731A JP2014528714A5 JP 2014528714 A5 JP2014528714 A5 JP 2014528714A5 JP 2014530731 A JP2014530731 A JP 2014530731A JP 2014530731 A JP2014530731 A JP 2014530731A JP 2014528714 A5 JP2014528714 A5 JP 2014528714A5

Authority

JP

Japan

Prior art keywords

cancer

isolated

seq

purified

cell

Prior art date

2012-09-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 210000004027 cell Anatomy 0.000 claims 25
• 229920001184 polypeptide Polymers 0.000 claims 16
• 102000004196 processed proteins & peptides Human genes 0.000 claims 16
• 108090000765 processed proteins & peptides Proteins 0.000 claims 16
• 125000003275 alpha amino acid group Chemical group 0.000 claims 13
• 102000004169 proteins and genes Human genes 0.000 claims 12
• 108090000623 proteins and genes Proteins 0.000 claims 12
• 102000039446 nucleic acids Human genes 0.000 claims 10
• 108020004707 nucleic acids Proteins 0.000 claims 10
• 150000007523 nucleic acids Chemical class 0.000 claims 10
• 239000000427 antigen Substances 0.000 claims 9
• 108091007433 antigens Proteins 0.000 claims 9
• 102000036639 antigens Human genes 0.000 claims 9
• 206010028980 Neoplasm Diseases 0.000 claims 6
• 201000011510 cancer Diseases 0.000 claims 6
• 239000013604 expression vector Substances 0.000 claims 6
• 238000000034 method Methods 0.000 claims 6
• 239000002773 nucleotide Substances 0.000 claims 6
• 125000003729 nucleotide group Chemical group 0.000 claims 6
• 238000003259 recombinant expression Methods 0.000 claims 6
• 201000001441 melanoma Diseases 0.000 claims 3
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims 3
• 239000008194 pharmaceutical composition Substances 0.000 claims 3
• 206010006187 Breast cancer Diseases 0.000 claims 2
• 208000026310 Breast neoplasm Diseases 0.000 claims 2
• 206010008342 Cervix carcinoma Diseases 0.000 claims 2
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
• 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
• 208000034578 Multiple myelomas Diseases 0.000 claims 2
• 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
• 206010033128 Ovarian cancer Diseases 0.000 claims 2
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
• 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
• 206010060862 Prostate cancer Diseases 0.000 claims 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
• 206010038389 Renal cancer Diseases 0.000 claims 2
• 208000000453 Skin Neoplasms Diseases 0.000 claims 2
• 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
• 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
• 201000010881 cervical cancer Diseases 0.000 claims 2
• 201000004101 esophageal cancer Diseases 0.000 claims 2
• 206010017758 gastric cancer Diseases 0.000 claims 2
• 208000014829 head and neck neoplasm Diseases 0.000 claims 2
• 201000010982 kidney cancer Diseases 0.000 claims 2
• 208000032839 leukemia Diseases 0.000 claims 2
• 201000007270 liver cancer Diseases 0.000 claims 2
• 208000014018 liver neoplasm Diseases 0.000 claims 2
• 201000005202 lung cancer Diseases 0.000 claims 2
• 208000020816 lung neoplasm Diseases 0.000 claims 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
• 201000002528 pancreatic cancer Diseases 0.000 claims 2
• 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
• 201000000849 skin cancer Diseases 0.000 claims 2
• 201000011549 stomach cancer Diseases 0.000 claims 2
• 201000002510 thyroid cancer Diseases 0.000 claims 2
• 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 2
• 210000001635 urinary tract Anatomy 0.000 claims 2
• SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 108010035452 HLA-A1 Antigen Proteins 0.000 claims 1
• 108010007655 HLA-C*70 antigen Proteins 0.000 claims 1
• 108091008874 T cell receptors Proteins 0.000 claims 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
• 210000001744 T-lymphocyte Anatomy 0.000 claims 1
• 239000002253 acid Substances 0.000 claims 1
• 230000000295 complement effect Effects 0.000 claims 1
• 238000001514 detection method Methods 0.000 claims 1
• 108020001507 fusion proteins Proteins 0.000 claims 1
• 102000037865 fusion proteins Human genes 0.000 claims 1
• 238000002955 isolation Methods 0.000 claims 1
• 238000012737 microarray-based gene expression Methods 0.000 claims 1
• 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1